Improved Skin Clearance Observed Among Patients With Psoriasis Treated With Combo Therapy
Research from the AAD annual meeting showed that clinical responses were maintained at week 96 for patients treated with secukinumab followed by bimekizumab.
“Through 1 year of the BE RADIANT Phase 3b trial, superior rates of complete skin clearance were observed with bimekizumab vs secukinumab,” explained study authors. “No new safety signals were identified.”
For this study, researchers observed patients who completed the 48-week double-blinded period. If they completed this trial period, they could enter the open-label extension. Each study participant received bimekizumab 320mg every 4 weeks or 8 weeks. Patients in the study received bimekizumab or secukinumab up to week 48 followed by bimekizumab to week 96 (bimekizumab/bimekizumab and secukinumab/ bimekizumab, respectively).
“Missing efficacy data were imputed as modified non-response,” the authors noted. “Patients who discontinued treatment due to lack of efficacy were considered non-responders; multiple imputation was used for other missing data.”
According to the findings, PASI100 was achieved by 74.8% of patients treated with bimekizumab vs 52.8% treated with secukinumab at week 48, and 70.6% bimekizumab/bimekizumab vs 76.1% secukinumab/ bimekizumab at week 96. Further, PASI≤2 was achieved by 94.3%of patients treated withhh bimekizumab vs 83.9% streated with ecukinumab at week 48 and 93.4% treated with bimekizumab/bimekizumab vs 94.6% treated with secukinumab/ bimekizumab at week 96.
Overall during the open-label extension, there was a low number of serious adverse events (AEs) reported. There was one death reported but the researchers did not consider it related to the treatment regimen. The most common AEs included, nasopharyngitis, oral candidiasis, and urinary tract infection.
Reference:
Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial. Poster presented at: AAD Annual Meeting; March 25-28, 2022; Boston, MA.
